Aselacin A

Aselacin A targets endothelin-1 receptor (ET-1 receptor), inhibits the the binding of ET-1 to ETA receptor and ETB receptor. Aselacin A inhibits the ET-1 binding to bovine atrial membrane and porcine cerebral membrane with IC50 of 22 μg/mL and 20 μg/mL. Aselacin A can be used for research of cardiovascular diseases[1].

Product Specifications

CAS Number

[156223-06-2]

UNSPSC

12352005

Target

Endothelin Receptor

Related Pathways

GPCR/G Protein

Field of Research

Cardiovascular Disease

Smiles

O=C1O[C@@H]([C@@H](C(NCCC(N[C@H](CC2=CNC3=C2C=CC=C3)C(N[C@H](CO)C(NC1)=O)=O)=O)=O)NC([C@@H](CCC(N)=O)NC(CCCCCCCC(/C=C/C=C/CCCCC)O)=O)=O)C

Molecular Formula

C46H68N8O11

Molecular Weight

909.08

References & Citations

[1]Jackson M, et al., Aselacins, novel compounds that inhibit binding of endothelin to its receptor. I. The producing organism, fermentation and biological activity. J Antibiot (Tokyo) . 1994 May;47 (5) :523-7.